Redeye provides an update on Saniona after the company's Q4 report, which offered few surprises.
Redeye provides an update on Saniona. In Q3, Saniona expectedly received the USD42.
Redeye returns with an update on Saniona. We are impressed by the company’s deal-making capabilities, having secured two landmark licensing ...
Redeye comments on the positive news that Saniona has outlicensed SAN2355 to Jazz Pharmaceuticals in epilepsy and other potential indication...
Redeye returns with an updated view of Saniona following the Q1 report and recent events in the company.
Redeye gives a short comment on the positive preliminary outcome of Saniona’s TO4 warrant program.
Redeye gives a short comment on yesterday’s news that Acadia and Saniona announced positive initial results from a phase I MAD study with AC...
Redeye returns with an updated view of Saniona following the Q4 report and recent events in the company.
Redeye gives a short comment on the news that Saniona’s partner Medix will file a final version of Tesofensine application in Mexico followi...
Redeye endorses today’s news that Cephagenix has secured funding of up to EUR9m and gives an initial comment.
Redeye returns with an updated view of Saniona following the Q3 report and the transformative licensing deal with Acadia.
Redeye briefly comments on the positive news that Saniona has outlicensed SAN711 to Acadia in neurological diseases.
Redeye gives a brief comment on today’s news regarding Tesofensine, indicating that Tesofensine has “not yet approved”.
Redeye has a positive view on the news from this morning, announcing that Saniona's collaboration with Boehringer Ingelheim has progressed t...
Redeye returns with an updated view of Saniona following the Q2 report and recent progress.
Redeye returns with an updated view of Saniona following the Q1 report and the recent pipeline update.
Redeye gives a short comment on Saniona’s pipeline update.
Redeye returns with an updated view of Saniona following the Q4 report and recent rights issue and reiterate our valuation.
Redeye adjusts its base case in light of the recent right issue.
Redeye is intrigued by today’s news that Saniona has selected an additional clinical candidate, the GABAA α5 negative allosteric modulator S...
Redeye is positive towards today’s news that Saniona has selected SAN2355 as the first clinical candidate from its KV7 epilepsy program, aft...
Redeye gives an initial comment on the news that Saniona has announced a rights issue of around to SEK140m.
Redeye returns with an updated view of Saniona following the Q3 report and recent milestones in the company.
Redeye endorses today’s news that Saniona has initiated the candidate selection phase for “a proprietary subtype selective frontrunner molec...
Redeye returns with an updated view of Saniona following the Q2 report.
Redeye is mostly positive to today’s news that Saniona has renegotiated its loan from Formue Nord.
Redeye is intrigued by today’s news that Saniona has entered into a collaboration agreement with the UK-based biotech company AstronauTx, wh...
Redeye returns with a view on Tesofensine following the positive opinion of the drug as an obesity treatment in Mexico by the technical comm...
Redeye is positively surprised by the favorable opinion for Tesofensine as an obesity treatment in Mexico by the technical committee of its ...
Redeye returns with a research update following the Q4 report and recent events in the company.
Redeye reviews the case of Saniona following continued positive progress lately.
Redeye endorses Saniona’s pre-clinical progress with drug candidate SAN903, that has compelling anti-inflammatory and anti-fibrotic properti...
Redeye is overall positive to today’s news that Saniona has amended its loan agreement with Formue Nord, which extends the company’s cash ru...
Saniona: Our Q2 Comment
Redeye is positive to the successful phase I outcome with SAN711 and raise our base case indicatively.
Redeye comments on Saniona’s Q1 report and our view of recent events.
Redeye gives a short comment on today’s update on the approval process for Tesofensine in Mexico.
Redeye is overall positive to the drastic, but necessary changes announced Monday, including a new management team, chairman and strategic f...
Redeye is discouraged by yesterday’s drastic announcement of a strategic reprioritization and thus pause of its two ongoing phase IIb studie...
Redeye comments on Saniona’s Q4 report and summarize our view of 2021.
Redeye is encouraged to learn that the ongoing SAN711 phase I study (n=80), now in the MAD (”multiple ascending dose”) phase, is progressing...
Saniona håller tidsplanen och inleder sin första fas 2b-studie på patienter med hypotalamisk fetma.
Saniona Q2’21 released yesterday showed the company progressing according to plans, we therefore leave our estimates and forecasts unchanged...
Saniona beviljas ny särläkemedelsstatus för Tesomet av FDA för patienter med hypotalamisk fetma.
Redeye argues that the orphan drug designation is another progress and milestone for the company.
Redeye (and the stock market) appraises that Saniona has secured SEK 80 mn in non-dilutive debt financing.
